Rigenerand S.r.l., founded in 2009 as a joint venture between Rand S.r.l. (a company active in the biomedical sector) and researchers of the University of Modena and Reggio Emilia, owns a Cell Factory, develops gene and cell therapies for the treatment of pancreatic cancer and innovative devices for three-dimensional cell cultures.

Fund: Principia III - Health
Investment Date April 2016
Sector: Biopharma